Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 312 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 3TC Clear all

Conditions: HIV Infections
Interventions: Abacavir sulfate, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Days to 2 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 12
States / cities: Gainesville, Florida • New Orleans, Louisiana • Baltimore, Maryland + 8 more

Conditions: HIV Infections
Interventions: L-756423, Indinavir sulfate, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Myers, Florida + 9 more

Conditions: HIV Infections
Interventions: VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 34
States / cities: Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more

Conditions: HIV Infections
Interventions: Hydroxyurea, Abacavir sulfate, Efavirenz, Didanosine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 23
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 19 more

Conditions: HIV-1 Infection
Interventions: ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 61
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more

Conditions: HIV Infections, Pregnancy
Interventions: Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 18
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more

Conditions: HIV Infections, Pregnancy
Interventions: Nelfinavir mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 7
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: Disease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV Infections
Interventions: Zidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 2 Days
Enrollment: 1,735 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Long Beach, California • Gainesville, Florida • Jacksonville, Florida + 2 more

Conditions: HIV-1 Infection
Interventions: BMS-986001, Placebo matching with BMS-986001, Efavirenz, Lamivudine, Tenofovir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: Sacramento, California • Orlando, Florida • West Palm Beach, Florida + 15 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Longbeach, California + 25 more

Conditions: HIV-1 Infection
Interventions: Dolutegravir, Lamivudine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 17 more

Conditions: HIV Infections, Pregnancy
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 5
States / cities: Miami, Florida • Detroit, Michigan • Memphis, Tennessee

Conditions: Hepatitis B
Interventions: Hepsera, Hepsera and lamivudine; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections, Hemophilia A
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more

Conditions: Hepatitis B Infection
Interventions: Tenofovir Disoproxil Fumarate, Lamivudine Oral Solution; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hepatitis B, Chronic
Interventions: Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Lamivudine, Sorbitol; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Relapsed/Refractory Solid Tumors
Interventions: Lamivudine, PD-L1 Blocker; Drug
Lead sponsor: Thomas Marron; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV-1 Infection
Interventions: F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 6 more

Search by objective public record fields.

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Reducing Vertical Transmission of Hepatitis B in Africa

Long-Term Lamivudine Therapy for Chronic Hepatitis B

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Lamivudine for Solid Tumors

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care